Posts tagged NASDAQ:ORMP
Oramed GLP-1 analog found safe in study

Oramed Pharmaceuticals (NASDAQ:ORMP) has successfully concluded a Phase 1b study of ORMD-0901, its oral GLP-1 analog, in Type 2 diabetes patients.

Read More
Oramed gets additional milestone from HTIT

Oramed Pharmaceuticals (NASDAQ:ORMP) has received a milestone payment of $4-million from Hefei Tianhui Incubator of Technologies (HTIT) of China.

The milestone is part of a license and investment agreement between Oramed and HTIT, and follows Oramed’s report of additional positive efficacy and safety data from a recently completed Phase 2b trial of its oral insulin product, ORMD-0801.

Read More
Oramed names Dr. Roy Eldor as CMD

Oramed Pharmaceuticals (NASDAQ:ORMP) appointed Dr. Roy Eldor to the newly created post of chief medical director.

“We are very pleased to welcome Dr. Eldor on board at this pivotal time for Oramed as we head towards a Phase 3 trial for our oral insulin capsule, ORMD-0801,” CEO, Nadav Kidron, said in a statement.

Read More
Oramed posts positive oral insulin Phase 2b results

Oramed Pharmaceuticals (NASDAQ:ORMP) has reported positive top-line results from its Phase 2b study, designed to evaluate the safety and efficacy of its oral insulin capsule, ORMD-0801, in patients with Type 2 diabetes.

The study’s primary objective, which is a significant reduction of weighted mean nighttime glucose, was successfully achieved.

Read More
Oramed receives patent in China

Oramed Pharmaceuticals (NASDAQ:ORMP) has received an official notification of granting patent right for the company’s patent for its invention titled, “Methods and Compositions for Oral Administrations of Proteins” by the State Intellectual Property Office of the People’s Republic of China.

The patent addresses Oramed’s platform technology, which underlies its products, including ORMD-0801, an orally ingestible insulin capsule.

Read More
USPTO extends Oramed patent term

The U.S. Patent and Trademark Office has issued a patent term adjustment (PTA) extending the patent term by 18 months for Oramed Pharmaceuticals’ (NASDAQ:ORMP) patent titled, “Methods and Compositions for Oral Administration of Proteins.”

Oramed had previously received an allowance on the patent. The PTA increases the patent term from the standard 20 years to 21 years and six months, extending the term through March 2028.

Read More
Oramed completes Phase 2b oral insulin study

Oramed Pharmaceuticals (NASDAQ:ORMP) said that all follow-up visits in its Phase 2b study of its oral insulin capsule, ORMD-0801, have been completed.

The double-blind, randomized Phase 2b study of 180 patients with Type 2 diabetes was initiated in mid-2015 and conducted at 33 clinical sites in the U.S.

Read More
Oramed gets Indian patent for oral administration of proteins

Oramed Pharmaceuticals’ (NASDAQ:ORMP) patent for its invention, titled “Methods and Compositions for Oral Administrations of Proteins” has been granted by the Indian Patent Office.

Oramed is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule, ORMD-0801. Having completed multiple Phase 2a trials, a Phase 2b trial in patients with Type 2 diabetes is ongoing under an IND with the FDA. In addition Oramed is developing an oral GLP-1 analog capsule, ORMD-0901.

Read More
Oramed Pharma issues letter to shareholders

In a letter to shareholders, Nadav Kidron, CEO of Oramed Pharmaceuticals (NASDAQ:ORMP), detailed the company’s recent achievements and future milestones.

“2015 was a very significant year for us at Oramed, setting the bar high for what we anticipate to be a momentous year ahead in 2016,” he added.

Read More